2-メトキシメチルサルビノリンB

2-メトキシメチルサルビノリンB
IUPAC命名法による物質名
	IUPAC名 (2S,4aR,6aR,7R,9S,10aS,10bR)- 9-(methoxymethoxy)- 2-(3-furanyl)dodecahydro-6a,10b-dimethyl-4,10-dioxo-2H-naphtho-[2,1-c]pyran-7-carboxylic acid methyl ester;
臨床データ
法的規制	Legal/Uncontrolled;
識別
ATCコード	none
PubChem	CID: 11407876
ChemSpider	23323947
ChEMBL	CHEMBL258098
化学的データ
化学式	C23H30O8
分子量	434 g/mol
	SMILES COCO[C@H]1C[C@H]([C@@]2(CC[C@H]3C(=O)O[C@@H](C[C@@]3([C@H]2C1=O)C)C4=COC=C4)C)C(=O)OC;
	InChI InChI=1S/C23H30O8/c1-22-7-5-14-21(26)31-17(13-6-8-29-11-13)10-23(14,2)19(22)18(24)16(30-12-27-3)9-15(22)20(25)28-4/h6,8,11,14-17,19H,5,7,9-10,12H2,1-4H3/t14-,15-,16-,17-,19-,22-,23-/m0/s1 ; Key:KFVUSZPWUZBAPF-AGQYDFLVSA-N ;
	テンプレートを表示

2-メトキシメチルサルビノリンB(2-Methoxymethyl Salvinorin B)は、科学研究に用いられる天然化合物サルビノリンAのアナログである半合成化合物である^[1]^[2]。サルビノリンAの活性が30分以下した続かないのに対して、約2-3時間の持続時間を持ち^[3]、κ-オピオイド受容体に対してより強いアフィニティーを持つ。関連化合物のヘルキノリンと同様に、2-メトキシメチルサルビノリンBは、サルビノリンAの脱アセチル化によって生じるサルビノリンBから得られる^[4]。サルビノリンAとサルビノリンBは、ともにサルビア・ディビノラムに含有されるが、サルビノリンAの方が収率が多い^[5]。

2-メトキシメチルサルビノリンBの、κ-オピオイド受容体に対する解離定数は、0.60 nMであり^[6]、動物実験によるとサルビノリンAよりも約5倍も強いが、2-エトキシメチルサルビノリンBの半分程度の強さである^[7]。

出典

^ Inan S, Lee DY, Liu-Chen LY, Cowan A (March 2009). “Comparison of the diuretic effects of chemically diverse kappa opioid agonists in rats: nalfurafine, U50,488H, and salvinorin A”. Naunyn-Schmiedeberg's Archives of Pharmacology 379 (3): 263–70. doi:10.1007/s00210-008-0358-8. PMID 18925386.
^ McLennan GP, Kiss A, Miyatake M, Belcheva MM, Chambers KT, Pozek JJ, Mohabbat Y, Moyer RA, Bohn LM, Coscia CJ (December 2008). “Kappa opioids promote the proliferation of astrocytes via Gbetagamma and beta-arrestin 2-dependent MAPK-mediated pathways”. Journal of Neurochemistry 107 (6): 1753–65. doi:10.1111/j.1471-4159.2008.05745.x. PMC 2606093. PMID 19014370.
^ Wang Y, Chen Y, Xu W, Lee DY, Ma Z, Rawls SM, Cowan A, Liu-Chen LY (March 2008). “2-Methoxymethyl-salvinorin B is a potent kappa opioid receptor agonist with longer lasting action in vivo than salvinorin A”. The Journal of Pharmacology and Experimental Therapeutics 324 (3): 1073–83. doi:10.1124/jpet.107.132142. PMC 2519046. PMID 18089845.
^ Lee DY, Karnati VV, He M, Liu-Chen LY, Kondaveti L, Ma Z, Wang Y, Chen Y, Beguin C, Carlezon WA, Cohen B (August 2005). “Synthesis and in vitro pharmacological studies of new C(2) modified salvinorin A analogues”. Bioorganic & Medicinal Chemistry Letters 15 (16): 3744–7. doi:10.1016/j.bmcl.2005.05.048. PMID 15993589.
^ Medana C, Massolino C, Pazzi M, Baiocchi C (2006). “Determination of salvinorins and divinatorins in Salvia divinorum leaves by liquid chromatography/multistage mass spectrometry”. Rapid Communications in Mass Spectrometry : RCM 20 (2): 131–6. doi:10.1002/rcm.2288. PMID 16331747.
^ Munro TA, Duncan KK, Xu W, Wang Y, Liu-Chen LY, Carlezon WA, Cohen BM, Béguin C (February 2008). “Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers”. Bioorganic & Medicinal Chemistry 16 (3): 1279–86. doi:10.1016/j.bmc.2007.10.067. PMC 2568987. PMID 17981041.
^ Baker LE, Panos JJ, Killinger BA, Peet MM, Bell LM, Haliw LA, Walker SL (April 2009). “Comparison of the discriminative stimulus effects of salvinorin A and its derivatives to U69,593 and U50,488 in rats”. Psychopharmacology 203 (2): 203–11. doi:10.1007/s00213-008-1458-3. PMID 19153716.

[pmid18925386-1] Inan S, Lee DY, Liu-Chen LY, Cowan A (March 2009). “Comparison of the diuretic effects of chemically diverse kappa opioid agonists in rats: nalfurafine, U50,488H, and salvinorin A”. Naunyn-Schmiedeberg's Archives of Pharmacology 379 (3): 263–70. doi:10.1007/s00210-008-0358-8. PMID 18925386.

[pmid19014370-2] McLennan GP, Kiss A, Miyatake M, Belcheva MM, Chambers KT, Pozek JJ, Mohabbat Y, Moyer RA, Bohn LM, Coscia CJ (December 2008). “Kappa opioids promote the proliferation of astrocytes via Gbetagamma and beta-arrestin 2-dependent MAPK-mediated pathways”. Journal of Neurochemistry 107 (6): 1753–65. doi:10.1111/j.1471-4159.2008.05745.x. PMC 2606093. PMID 19014370.

[pmid18089845-3] Wang Y, Chen Y, Xu W, Lee DY, Ma Z, Rawls SM, Cowan A, Liu-Chen LY (March 2008). “2-Methoxymethyl-salvinorin B is a potent kappa opioid receptor agonist with longer lasting action in vivo than salvinorin A”. The Journal of Pharmacology and Experimental Therapeutics 324 (3): 1073–83. doi:10.1124/jpet.107.132142. PMC 2519046. PMID 18089845.

[pmid15993589-4] Lee DY, Karnati VV, He M, Liu-Chen LY, Kondaveti L, Ma Z, Wang Y, Chen Y, Beguin C, Carlezon WA, Cohen B (August 2005). “Synthesis and in vitro pharmacological studies of new C(2) modified salvinorin A analogues”. Bioorganic & Medicinal Chemistry Letters 15 (16): 3744–7. doi:10.1016/j.bmcl.2005.05.048. PMID 15993589.

[pmid16331747-5] Medana C, Massolino C, Pazzi M, Baiocchi C (2006). “Determination of salvinorins and divinatorins in Salvia divinorum leaves by liquid chromatography/multistage mass spectrometry”. Rapid Communications in Mass Spectrometry : RCM 20 (2): 131–6. doi:10.1002/rcm.2288. PMID 16331747.

[pmid17981041-6] Munro TA, Duncan KK, Xu W, Wang Y, Liu-Chen LY, Carlezon WA, Cohen BM, Béguin C (February 2008). “Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers”. Bioorganic & Medicinal Chemistry 16 (3): 1279–86. doi:10.1016/j.bmc.2007.10.067. PMC 2568987. PMID 17981041.

[pmid19153716-7] Baker LE, Panos JJ, Killinger BA, Peet MM, Bell LM, Haliw LA, Walker SL (April 2009). “Comparison of the discriminative stimulus effects of salvinorin A and its derivatives to U69,593 and U50,488 in rats”. Psychopharmacology 203 (2): 203–11. doi:10.1007/s00213-008-1458-3. PMID 19153716.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

関連項目

出典